The search for next-gen oncology therapies has sparked an arms race in biopharma to find the next big thing—whether that’s in cell and gene therapies or promising antibody-drug conjugates (ADCs). Eyeing that bustling market, Swiss manufacturing giant Lonza is diving even further into ADCs with a new customer on board.
As part of a tie-up with an undisclosed customer, Lonza will build two manufacturing suites totaling 16,146 square feet dedicated to the commercial production of two cancer fighting ADCs, the company said Wednesday. The newest expansion at Lonza’s Visp, Switzerland facility is set to go online at the end of 2022 and will eventually employ 200 workers.
With a growing number of approvals in recent years, ADCs have become a target of major biopharma investment despite the highly specialized manufacturing process required to produce them. Products like Gilead Sciences’ Trodelvy and AstraZeneca’s Enhertu are both blockbuster candidates, according to analysts, with potential for more winners in the near future.
Free Webinar
What could you do with real-time supply chain information at your fingertips?
Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!
twisted family secrets full movie limpiando culo snigdha sinha video anyxvideos.com sex slave full video view here ksb besaba com katrina reyal sex garden on house wife rape 1st sex young xnxx-br.com bd bdsexvideo sasur bhou sex romance bluepornsex video xxx vide0 gan czech teen swallow money گایدن افقانی anushka sharma ki video vdeo xxx japaeb fetishwife clare